Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | LDHB | P07195 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 4/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994953 | 0.83 | LDHA (0.52) | LDHALDHBCCNT1CDK9ATP1A1 | |
| SCHEMBL1997719 | 0.83 | LDHA (0.47) | LDHALDHBCCNT1CDK9PLK1 | |
| SCHEMBL12614041 | 0.83 | LDHA (0.47) | LDHALDHBCCNT1CDK9PLK1 | |
| SCHEMBL1995476 | 0.83 | JAK2 (0.48) | LDHALDHBCCNT1CDK9PLK1 | |
| SCHEMBL1994317 | 0.83 | LDHA (0.47) | LDHALDHBCCNT1CDK9PLK1 | |
| SCHEMBL1995095 | 0.81 | LDHA (0.47) | LDHALDHBCCNT1CDK9ATP1A1 | |
| SCHEMBL1996364 | 0.81 | FLT3 (0.48) | LDHALDHBCCNT1CDK9PLK1 | |
| SCHEMBL1997500 | 0.81 | IRAK4 (0.50) | LDHALDHBCCNT1CDK9ATP1A1 | |
| SCHEMBL1997497 | 0.81 | IRAK4 (0.50) | LDHALDHBCCNT1CDK9ATP1A1 | |
| SCHEMBL1993107 | 0.80 | LDHA (0.46) | LDHALDHBCCNT1CDK9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | LDHA 3822/4885LDHB 3917/4885CCNT1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.